Awareness of, and behavioural responses to, drug alerts in Australia: Findings from the Ecstasy and Related Drugs Reporting System and the Illicit Drug Reporting System

AMY PEACOCK1,2, RAIMONDO BRUNO2,1, MONICA J. BARRATT3,4,1, NADINE EZARD1,5,6, PENNY HILL1,5,7, MARY E. HARROD8, JARED A. BROWN9,10, ROBERT PAGE1,6, JOEL KEYGAN2, HARRY SUMNALL11, RACHEL SUTHERLAND1

1National Drug and Alcohol Research Centre, UNSW Sydney, Sydney, Australia, 2School of Psychological Sciences, University of Tasmania, Hobart, Australia, 3Social and Global Studies Centre, RMIT University, Melbourne, Australia, 4Digital Ethnography Research Centre, RMIT University, Melbourne, Australia, 5National Centre for Clinical Research on Emerging Drugs, Sydney, Australia, 6St Vincent’s Hospital, Sydney, Australia, 7Behaviours and Health Risks Program, Burnet Institute, Melbourne, Australia, 8NSW Users and AIDS Association, Sydney, Australia, 9New South Wales Poisons Information Centre, The Children’s Hospital at Westmead, Westmead, Sydney, Australia, 10Centre for Alcohol and Other Drugs, NSW Ministry of Health, St Leonards, Australia, 11Faculty of Health, Liverpool John Moores University, Liverpool, UK

Presenter’s email: Amy.Peacock@unsw.edu.au

Introduction and Aims: ‘Drug alerts’ are notices sharing urgent health information about specific drugs carrying high risk of harm. The aims of this study were to assess awareness of, and behavioural responses to, drug alerts among Australians who use illegal drugs.

Design and Methods: Between April-August 2021, 774 people who use ecstasy and/or other illegal stimulants and 888 people who inject drugs recruited from capital cities completed a face-to-face interview (including questions on drug alerts) for the Ecstasy and Related Drugs Reporting System (EDRS) and Illicit Drug Reporting System (IDRS), respectively.

Results: Two-fifths (41%) and one-third (32%) of the EDRS and IDRS samples were aware of a drug alert from the past 12 months, respectively. ‘Ecstasy/MDMA containing other drugs’ was the most commonly endorsed alert in the total EDRS sample (20%), and ‘heroin containing other drugs’ in the IDRS sample (18%). In both samples, greatest awareness of alerts was recorded among New South Wales participants. Social media was the most common means of receiving alerts among EDRS participants, and in person among IDRS participants. Less than one-in-ten of those who had seen an alert in both samples tried to obtain the drug referenced in the alert, approximately one-quarter adopted additional harm reduction behaviours, and approximately one-fifth shared the alert with peers.

Discussions and Conclusions: A significant minority of people who use illegal drugs in Australia are aware of drug alerts, notable given that alerts are only released by several jurisdictional/local health agencies. Increased harm reduction behaviour and information sharing with peers are outcomes of such communication.

Implications for Practice or Policy: These findings support the continuation and expansion of risk communication via drug alerts in Australia. The results reinforce the importance of reviewing and finessing communication of drug alerts to ensure intended outcomes are being achieved, and that the needs of people who use illegal drugs are being met.

Disclosure of Interest Statement: The National Drug and Alcohol Research Centre (including the EDRS and IDRS projects) and the National Centre for Clinical Research in Emerging Drugs are supported by funding from the Australian Government Department of Health. AP has received untied educational grants from Seqirus and Mundipharma. RS has received untied educational grants from Seqirus. RB has received untied educational grants.
from Mundipharma and Indivior. Funding from these organisations has now ceased, funding was for work unrelated to this project, and the funding bodies had no role in study design, analysis and reporting. No pharmaceutical grants were received for this study. NE and RP are employed by St Vincent's Hospital in the NSW Health public health service. AP and RS are supported by a National Health and Medical Research Council Investigator Fellowship.